Navigation Links
New vaccine for condition that kills 500,000 children a year

fatal.

Efforts to eradicate rotavirus disease were almost derailed in 1999 when another vaccine was pulled from the market because it caused a rare bowel obstruction called intussusception at a rate of one in 10,000 patients. Intussusception takes place when the bowel folds in on itself, causing an intestinal blockage.

Because the bowel obstruction was so rare, and the increased incidence was so small, the only way to evaluate the safety of a new rotavirus vaccine was to launch a clinical trial involving more than 60,000 infants.

In 2000, Merck asked Matson to serve as the U.S. principal investigator in a clinical trial of RotaTeq, a vaccine under development.

RotaTeq targets five major strains of rotavirus, which account for 90 percent of rotavirus disease. The trial involved infants in the United States, Belgium, Costa Rica, Finland, Germany, Guatemala, Italy, Jamaica, Mexico, Sweden and Taiwan.

Infants were randomly assigned to receive three doses of vaccine or placebo, given four to 10 weeks apart. Because of the bowel obstruction associated with the withdrawn vaccine, a primary goal of the study was to determine whether RotaTeq was safe. Overall, 68,038 infants between six and 12 weeks participated, 34,035 in the vaccine group and 34,003 in the placebo group. All were monitored for serious adverse events, including intussusception.

During the study, infants who received the vaccine actually had a lower incidence of intussusception: 12 cases among vaccine recipients and 15 among those who received a placebo. No other significant side effects or complications were reported.

Rotateq also proved to be effective, nearly eliminating serious rotavirus-related gastroenteritis. The vaccine reduced rotavirus-related hospital admissions by 96 percent. In addition, RotaTeq reduced rotavirus-related emergency rooms visits by 94 percent, and doctor's office visits by 86 percent.

"The protective effect is stron
'"/>

Source:Eastern Virginia Medical School


Page: 1 2 3

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New vaccine for condition that kills children year

(Date:7/10/2014)... July 9, 2014 The widespread adoption ... large part by meaningful use and related federal ... interact with laboratory information. Now, more than ever, ... of clinical informatics in order to deliver high ... address the educational needs of pathologists in this ...
(Date:7/10/2014)... The vegetable oil found in your popcorn or soap might ... get even worse, according to an analysis in the Cell ... The growing demand for vegetable oil has already led to ... bringing trouble for orangutans in particular. If guidelines are not ... those large-scale industrial plantations from Asia into Africa will be ...
(Date:7/10/2014)... The Marshall Institute for Interdisciplinary Research (MIIR) and ... Medicine today announced they will be partnering with ... drugs. , Under the agreement with Shanghai-based HD ... the costs and risks of discovery and development ... own any intellectual property and commercialization rights to ...
Breaking Biology News(10 mins):New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4Hunger for vegetable oil means trouble for Africa's great apes 2Marshall University to partner with international company in drug development venture 2
... nest boxes used to aid cavity-nesting ducks can prove to ... by University of Cincinnati Educator Associate Professor Denis Conover, of ... Arts and Sciences, when he came upon a duck nest ... The box had tipped over. Turtle corpses were strewn about ...
... The debate may largely be drawn along political lines, but ... most controversial questions in 21st century science. Writing in ... Center for Atmospheric Research, argues that the evidence for anthropogenic ... proof should lie with research which seeks to disprove the ...
... chilly inside your house, you might just turn the heater ... to a toastier and more comfortable state until it warms ... long thought cells would respond to their environment in a ... Institute of Technology (Caltech) are finding that cells can respond ...
Cached Biology News:UC research finds that a duck's boon might be a turtle's bane 2The human cause of climate change: Where does the burden of proof lie? 2Caltech researchers find pulsating response to stress in bacteria 2Caltech researchers find pulsating response to stress in bacteria 3
(Date:7/11/2014)... Research and Markets  has announced the ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is ... or RNA) into cells. This technology helps the cells ... protein metabolism by affecting the nuclear genes. The transfection ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... (PCR) TECHNOLOGY: GLOBAL MARKETS , the global market for ... billion in 2013. This is estimated to grow to ... growth rate (CAGR) of 28.6%. , New digital PCR ... possibilities within the broader PCR field. The opportunities presented ...
(Date:7/11/2014)... EPFL and the University of  Geneva  (UNIGE) ... P. Donoghue . The American neuroscientist is to head ... The new Wyss Center for Bio- and Neuro-Engineering, ... , has named as its director one of the ... founder of Brown University,s Institute for Brain Science, has ...
(Date:7/11/2014)... ON , July 11, 2014 /CNW/ - Sunovion ... approved APTIOM TM (eslicarbazepine acetate) for use as ... seizures in patients with epilepsy who are not satisfactorily ... indicated for use in patients under 18 years of ... most common neurological disorders and according to Epilepsy Canada, ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4
... Mass. and WASHINGTON, Oct. 21 Boston,Scientific Corporation ... an analysis,of nearly 7,000 patients from its TAXUS ... performance of the TAXUS(R) Express2(TM) Paclitaxel-Eluting,Coronary Stent System ... low incidences of adverse events and repeat,revascularization through ...
... New Cases of Chagas, Disease ... & Blood Transfusions, ANAHEIM, Calif., Oct. 20 In ... the first blood-screening test,for Chagas, disease, some 241 blood donations ... the parasite known to cause,this serious and potentially fatal parasitic ...
... of AACR Virtual Meeting -, LOS ANGELES, Oct. ... announced that Kathleen Danenberg, the Company,s,President and Chief Executive ... in tailoring medicine at the 2007 AACR-NCI-EORTC,International Conference on ... 22-26, 2007 at the Moscone Convention Center,West in San ...
Cached Biology Technology:ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 2ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 4Blood Donations in U.S. Testing Positive for Chagas' Disease 2Blood Donations in U.S. Testing Positive for Chagas' Disease 3Blood Donations in U.S. Testing Positive for Chagas' Disease 4Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 2Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 3
Hybridization Buffer 3.6 ml...
Olig2 Immunogen: Synthetic peptide from rat. Available Date: 9-19-2006...
Mouse monoclonal [0.N.305] to G protein alpha - BSA and Azide free ( Abpromise for all tested applications). Antigen: Partially purified G protein alpha from rat brain. Entrez GeneID: 2778 ...
Proteinase K Buffer 3.9 ml...
Biology Products: